Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.39% | 30.68% | -11.20% | 42.64% | 38.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -114.72% | -124.78% | -36.83% | -81.19% | -77.32% |
| Change in Net Operating Assets | -30.88% | 141.46% | 132.51% | -2,223.85% | 12.91% |
| Cash from Operations | -7.52% | -7.03% | 1.44% | -53.28% | -57.55% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 59.39% | 66.24% | 84.41% | -5.87% | -215.71% |
| Cash from Investing | 59.39% | 69.45% | 86.36% | -7.48% | -225.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28.93% | 121.29% | 167.26% | 168.48% | 187.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -100.00% | -100.00% | -42.56% |
| Repurchase of Preferred Stock | -- | -- | 98.28% | 97.19% | 97.19% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -194.83% | 22.24% | 91.46% | 91.46% | 68.27% |
| Cash from Financing | -24.79% | -36.43% | -26.07% | -55.20% | 13.80% |
| Foreign Exchange rate Adjustments | -- | -150.00% | 133.33% | -90.00% | -112.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.29% | 67.11% | 118.93% | -193.76% | -165.31% |